#1 Clinical Trials Search in Europe

Study on Avelumab and Cetuximab for Patients with Metastatic Colorectal Cancer Who Have Previously Received Treatment

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a combination treatment for patients with metastatic colorectal cancer, a type of cancer that has spread from the colon or rectum to other parts of the body. The study involves two medications: avelumab and cetuximab. Avelumab is a type of medication known as a human monoclonal antibody, which is a protein designed to help the immune system fight cancer. Cetuximab is another monoclonal antibody that targets specific proteins on cancer cells to stop their growth.

The purpose of this study is to evaluate how effective the combination of avelumab and cetuximab is compared to using cetuximab alone in patients who have already received treatment for their cancer. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 12 months, during which the participants’ health and response to the treatment will be closely monitored.

Throughout the study, researchers will assess various outcomes, including the overall survival time, which is the length of time patients live after starting the treatment. They will also look at how many patients experience a reduction in cancer size and how long patients live without the cancer getting worse. Safety will be monitored by checking for any side effects and conducting regular health assessments. This study aims to provide valuable information on whether the combination of avelumab and cetuximab can offer better outcomes for patients with metastatic colorectal cancer.

1 enrollment

Upon joining the study, the patient is enrolled after meeting specific criteria, including age, health status, and previous treatment history.

The patient must have a confirmed diagnosis of metastatic colorectal cancer and meet other health-related criteria.

2 randomization

The patient is randomly assigned to one of two groups: one receiving a combination of avelumab and cetuximab, and the other receiving cetuximab alone.

This process ensures that the study results are unbiased and scientifically valid.

3 treatment administration

The patient receives the assigned treatment through an IV infusion.

The dosage and frequency of administration are determined by the study protocol and the patient’s health status.

4 monitoring and assessments

Throughout the trial, the patient’s health is closely monitored through regular assessments, including clinical laboratory tests, vital signs, and electrocardiograms (ECGs).

The patient’s response to the treatment is evaluated using specific criteria to determine any changes in the disease.

5 follow-up

After completing the treatment phase, the patient enters a follow-up period where their health and any long-term effects of the treatment are monitored.

This phase helps gather data on the overall survival and progression-free survival of the patient.

Who Can Join the Study?

  • Sign a written informed consent form before any trial-related procedures that are not part of standard care.
  • Have an ECOG PS of 0 to 1 at trial entry. ECOG PS stands for Eastern Cooperative Oncology Group Performance Status, which measures how well you can perform daily activities.
  • Have an estimated life expectancy of more than 12 weeks.
  • Have adequate blood function, which means having certain levels of white blood cells, neutrophils, lymphocytes, platelets, and hemoglobin.
  • Have adequate liver function, which means having certain levels of bilirubin, AST, and ALT. These are substances measured in the blood to check liver health.
  • Have adequate kidney function, which means having a creatinine clearance greater than 30 mL/min. This measures how well your kidneys are working.
  • Use effective contraception if there is a risk of pregnancy, for both men and women, during the study and for at least 2 months after the last treatment. This is important because the effects of the trial drug on an unborn baby are unknown.
  • Be 18 years of age or older.
  • Have a confirmed diagnosis of colorectal adenocarcinoma, which is a type of cancer that starts in the colon or rectum.
  • Have a diagnosis of metastatic disease, meaning the cancer has spread to other parts of the body.
  • Have RAS and BRAF wild-type status in a liquid biopsy at initial diagnosis. This means certain genes in the cancer cells do not have specific mutations.
  • Have shown a major response to a first-line therapy containing an anti-EGFR drug. This means the cancer significantly shrank or disappeared with the first treatment.
  • Have received a second-line therapy.
  • Have more than 4 months since the last dose of an anti-EGFR drug given in the first-line treatment before joining the study.
  • Have measurable disease according to RECIST criteria v1.1. This means the cancer can be measured in size using specific guidelines.

Who Cannot Join the Study?

  • Patients with a different type of cancer other than colorectal metastatic cancer cannot participate. This means the cancer must have started in the colon or rectum and spread to other parts of the body.
  • Patients who have not been previously treated for their cancer are not eligible. This study is for those who have already received treatment.
  • Patients with genetic mutations in the RAS or BRAF genes are excluded. These are specific genes that can affect how cancer grows.
  • Patients who are not within the specified age range cannot participate. The study is open to adults only.
  • Both male and female patients are eligible, but those who are pregnant or breastfeeding may be excluded for safety reasons.
  • Patients who are part of a vulnerable population, such as those unable to give informed consent, are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliero Universitaria Careggi Florence Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Azienda Ospedaliero Universitaria Di Sassari Sassari Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy

Other Sites

Site Name City Country Status
Ospedale Vito Fazzi Lecce Lecce Italy
Centro Di Riferimento Oncologico Di Aviano Aviano Italy
Istituto Europeo Di Oncologia S.r.l. Milan Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale Naples Italy
Casa Sollievo Della Sofferenza San Giovanni Rotondo Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo Italy
ARNAS Garibaldi Di Catania Catania Italy
National Institute Of Gastroenterology Saverio De Bellis Research Hospital Castellana Grotte Italy
ARNAS Civico Di Cristina Benfratelli Palermo Italy
Azienda Ospedaliera Ordine Mauriziano Di Torino Turin Italy
AORN San Giuseppe Moscati Avellino Avellino Italy
Fondazione Poliambulanza Brescia Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi Ancona Italy
Azienda Sanitaria Locale Napoli 1 Centro Naples Italy
Pia Fondazione Di Culto E Religione Card G Panico Tricase Italy
Ospedale S G Moscati Statte Italy
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Universita’ Degli Studi Di Verona Verona Italy
IRCCS Ospedale Policlinico San Martino Genoa Italy
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Orrzvgdn &ncjchq Cyhyyb Mdzfa Pxdsoarjrpciwd Apipdn Ragusa Italy
Ijhviqaj Rzsdqpfye Pfl Lv Sfyvbo Dzl Tovbzy Dkfj Arzftvu Ihsv Szdqvx Meldola Italy
Abnpruj Ulv Ipttk Ds Rtkqjb Edrqti Reggio Emilia Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Recruiting
21.07.2022

Trial locations

Investigated drugs:

Avelumab is a type of medication known as an immune checkpoint inhibitor. It works by helping the immune system recognize and attack cancer cells more effectively. In this trial, it is being used to see if it can improve survival in patients with a specific type of colorectal cancer.

Cetuximab is a targeted therapy that works by blocking a protein on the surface of cancer cells, which can slow down or stop their growth. It is used in this trial both alone and in combination with avelumab to determine if the combination is more effective than cetuximab alone in treating colorectal cancer.

Investigated diseases:

Colorectal Metastatic Cancer – This is a type of cancer that begins in the colon or rectum and has spread to other parts of the body. It often progresses through stages, starting in the lining of the colon or rectum and potentially moving to nearby lymph nodes and distant organs, such as the liver or lungs. The spread of cancer cells to other parts of the body is known as metastasis. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort. As the disease advances, it can lead to more severe symptoms and complications. The progression and impact of the disease can vary based on the location and extent of the spread.

Trial ID:
2024-519481-44-00
Protocol code:
CAVE-2
NCT ID:
NCT05291156
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4

  • A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

    Recruiting

    2 1 1
    Investigated diseases:
    Italy The Netherlands